Fatal Tolperisone Poisoning: Autopsy and Toxicology findings in Three Suicide Cases

Total Page:16

File Type:pdf, Size:1020Kb

Fatal Tolperisone Poisoning: Autopsy and Toxicology findings in Three Suicide Cases Forensic Science International 215 (2012) 101–104 Contents lists available at ScienceDirect Forensic Science International jou rnal homepage: www.elsevier.com/locate/forsciint Fatal tolperisone poisoning: Autopsy and toxicology findings in three suicide cases a, b,1 a,2 a,3 Frank Sporkert *, Christophe Brunel , Marc P. Augsburger , Patrice Mangin a University Centre of Legal Medicine Lausanne-Geneva, Rue du Bugnon 21, CH-1011 Lausanne, Switzerland b University Centre of Legal Medicine Lausanne-Geneva, Rue Michel-Servet 1 – CH-1211 Geneva 4, Switzerland A R T I C L E I N F O A B S T R A C T 1 Article history: Tolperisone (Mydocalm ) is a centrally acting muscle relaxant with few sedative side effects that is used Received 30 September 2010 for the treatment of chronic pain conditions. We describe three cases of suicidal tolperisone poisoning in Received in revised form 19 May 2011 three healthy young subjects in the years 2006, 2008 and 2009. In all cases, macroscopic and microscopic Accepted 20 May 2011 autopsy findings did not reveal the cause of death. Available online 17 June 2011 Systematic toxicological analysis (STA) including immunological tests, screening for volatile substances and blood, urine and gastric content screening by GC–MS and HPLC–DAD demonstrated Keywords: the presence of tolperisone in all cases. In addition to tolperisone, only the analgesics paracetamol Tolperisone (acetaminophen), ibuprofen and naproxen could be detected. The blood ethanol concentrations were all Muscle relaxant lower than 0.10 g/kg. Tolperisone was extracted by liquid–liquid extraction using n-chlorobutane as the Fatal poisoning Suicide extraction solvent. The quantification was performed by GC–NPD analysis of blood, urine and gastric Lethal intoxication content. Tolperisone concentrations of 7.0 mg/l, 14 mg/l and 19 mg/l were found in the blood of the deceased. In the absence of other autopsy findings, the deaths in these three cases were finally explained as a result of lethal tolperisone ingestion. To the best of our knowledge, these three cases are the first reported cases of suicidal tolperisone poisonings. ß 2011 Elsevier Ireland Ltd. All rights reserved. 1. Introduction polysynaptic reflex activity [4,5]. Because it has fewer sedative side effects than other muscle relaxants, psychomotoric Tolperisone, 2-methyl-1-(4-methylphenyl)-3-(piperidinyl)-1- impairment (driving, operation of machines) is strongly propanone (chemical structure in Fig. 1), was first described as a reduced. Possibly critical side effects of tolperisone were centrally acting muscle relaxant by Porszasz et al. in 1961 [1]. In reported by Ribi et al. in four patients at the University Hospital contrast to peripheral muscle relaxants and neuromuscular- of Geneva between November 2001 and March 2003; these side blocking drugs such as curare derivatives, centrally acting muscle effects included vasodilatation, hypotension and anaphylactic relaxants, also referred to as spasmolytics, such as carisoprodol, reactions [6]. baclofen, clonidine, diazepam, tetrazepam and gabapentin, act at the A typical treatment regimen for tolperisone is 3 Â 50 mg per level of the cortex, brain stem or spinal cord. Tolperisone, eperisone, day (max. 600 mg), ingested orally. The oral bioavailability is low, inaperisone, lanperisone and silperisone are the best known drugs approximately 20%. The maximum plasma concentrations, 64– within the group of the piperidine derivatives [2]. Tolperisone is 785 ng/ml (average 297 ng/ml), were measured after oral admin- generally used as a racemic mixture. After injection of the active istration of 450 mg tolperisone [7]. Tolperisone is mainly stereoisomer, tolperisone is rapidly converted into the racemate [3]. metabolized by CYP2D6. The main metabolites are hydroxy- + Tolperisone inhibits voltage-dependant Na -channels in the methyl-tolperisone (by hydroxylation) and hydroxy-tolperisone brain-stem and, as a result, inhibits pathologic mono- and (by reduction). The elimination half-life varies from 43 min to 174 min depending on the application [7,8]. The biphasic elimination after administration of a single dose is completed * Corresponding author. Tel.: +41 21 314 56 26, fax: +41 21 314 73 29. after 24 h. E-mail addresses: [email protected] (F. Sporkert), To the best of our knowledge, no data about toxic and lethal [email protected] (C. Brunel), [email protected] tolperisone concentrations have been published in the scientific (M.P. Augsburger), [email protected] (P. Mangin). 1 literature. Only one case of suicidal ingestion of a mixture of ten Tel.: +41 22 379 56 19. 2 drugs including tolperisone, yielding a tolperisone blood concen- Tel.: +41 21 314 70 85. 3 Tel.: +41 21 314 70 64. tration of 3.36 mg/kg, was found in the literature [9]. 0379-0738/$ – see front matter ß 2011 Elsevier Ireland Ltd. All rights reserved. doi:10.1016/j.forsciint.2011.05.025 102 F. Sporkert et al. / Forensic Science International 215 (2012) 101–104 TIC: T05 .D\data.ms 9.89 6 1.4e +07 1.2e +07 7.91 9 1e+07 7.84 5 Tolperisone 8000000 12.92 3 6000000 18.99 4 Abundance 15.63 8 19.51 6 4000000 8.824 13.38 7 13.821 16.794 19.58 2 5.199 14.82 5 16.482 17.1217.40 72 2000000 11.1811.822 9 14.039 25.91 6 6.00 8.00 10.00 12.00 14.00 16.00 18.00 20.00 22.00 24.00 26.00 28.00 Time--> 98.2 Scan 1749 (12.929 min): T05.D\data.ms 2800000 91 CH3 2400000 98 O 2000000 119 N * 1600000 CH3 Abundance 1200000 800000 400000 91.1 (M-CH )+ M+ 55.2 119.1 3 77.1 138.1 161.2 184.1202.2 230.2 245.3 0 60 80 100120140160180200220240260280 m/z--> Fig. 1. Total ion chromatogram (TIC) and MS spectra of tolperisone in the blood extract of case 2 and corresponding library spectra (MPW2007). 40, 60 and 48 h, respectively, after the death. Post-mortem serum was obtained by 2. Case histories direct centrifugation of peripheral femoral blood during autopsy. Blood, urine and gastric contents were submitted to a systematic toxicological Case 1: A 14-year-old female was found dead at home by her analysis according to our routine procedure [10]. relatives in 2006. No sign of struggle was observed at the place of death. According to the police investigation, the girl had attempted 3.2. Reagents suicide using drugs four months earlier. Tolperisone hydrochloride, paracetamol, naproxen sodium, ibuprofen sodium, Case 2: A 20-year-old female was found dead in her boyfriend’s and 5-(p-methylphenyl)-5-phenylhydantoin (MPPH) were obtained from Sigma– home in 2008. A suicide note and several drugs, among them Aldrich (Buchs, Switzerland). The internal standard (I.S.) methaqualone was tolperisone, were discovered at the place of death. obtained from Lipomed (Arlesheim, Switzerland). Sodium chloride (p.a.), potassium Case 3: A 41-year-old female was found dead in the summer of dihydrogen phosphate (p.a.), ammonium chloride (p.a.), ammonium hydroxide (25%), acetonitrile (HPLC grade), ethyl acetate (GC grade), methanol (GC grade), n- 2009 in a forest. Three years before, she had obtained a 1 chlorobutane (GC grade), and toluene (GC grade) were purchased from Sigma– Mydocalm prescription because of psychosomatic pain. No sign Aldrich (Buchs, Switzerland). of crime or drug ingestion was noted at the place of death. The external examinations of the bodies were unremarkable, 3.3. Solutions and the macro- and microscopic autopsy findings all showed Stock solutions were prepared at 1 mg/ml in methanol for tolperisone and visceral congestion and lung edema. The autopsy findings did not methaqualone and at 10 mg/ml for paracetamol, ibuprofen, naproxen and MPPH. reveal the cause of death in any of the three cases. Working solutions of tolperisone and the I.S. were at 10 mg/ml in methanol. For quality controls, second working and stock solutions of tolperisone with the same concentrations as above were prepared. 3. Material and methods 3.1. Samples 3.4. Extraction procedures Biological fluids and tissue samples of the three autopsy cases were routinely Blood, post-mortem serum, urine, cerebrospinal fluid, bile and gastric contents taken during autopsy at the University Center of Legal Medicine of Lausanne and were extracted according to the following procedures: to 0.5 ml of each liquid were immediately frozen and kept until analysis at À21 8C. The autopsies took place sample (for bile and gastric content, 0.01 ml of the homogenized sample), 100 ml of F. Sporkert et al. / Forensic Science International 215 (2012) 101–104 103 the I.S. solution at 10 mg/l (final concentration, 1000 mg/l) and 2 ml of saturated Additionally, external calibration was performed from 0.1 to 10 mg/l at seven ammonium chloride buffer (pH 9.5) were added. n-Chlorobutane (4 ml) was used as different concentrations (0.1, 0.2, 0.4, 1.0, 2.0, 5.0 and 10 mg/l) in drug-free whole the extraction solvent because of its good efficiency in an extraction test [11]. After bovine blood (EDTA stabilized). Six tolperisone free blood extracts were injected on a 15 min extraction on a horizontal shaker at 200 strokes/min, the samples were the GC–NPD in order to test the system’s selectivity. centrifuged for 5 min at 4000 rpm. The upper layer was collected and evaporated to Because no commercial quality control sample was available, an internal quality dryness at 30 8C under a gentle stream of nitrogen. The residue was dissolved in control sample based on an independent stock solution of 1.0 mg/l was prepared 100 ml of toluene. Liver and brain tissues (each 0.5 g, to which was added 1 ml of and analyzed in the same way.
Recommended publications
  • WHO Drug Information Vol. 12, No. 3, 1998
    WHO DRUG INFORMATION VOLUME 12 NUMBER 3 • 1998 RECOMMENDED INN LIST 40 INTERNATIONAL NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES WORLD HEALTH ORGANIZATION • GENEVA Volume 12, Number 3, 1998 World Health Organization, Geneva WHO Drug Information Contents Seratrodast and hepatic dysfunction 146 Meloxicam safety similar to other NSAIDs 147 Proxibarbal withdrawn from the market 147 General Policy Issues Cholestin an unapproved drug 147 Vigabatrin and visual defects 147 Starting materials for pharmaceutical products: safety concerns 129 Glycerol contaminated with diethylene glycol 129 ATC/DDD Classification (final) 148 Pharmaceutical excipients: certificates of analysis and vendor qualification 130 ATC/DDD Classification Quality assurance and supply of starting (temporary) 150 materials 132 Implementation of vendor certification 134 Control and safe trade in starting materials Essential Drugs for pharmaceuticals: recommendations 134 WHO Model Formulary: Immunosuppressives, antineoplastics and drugs used in palliative care Reports on Individual Drugs Immunosuppresive drugs 153 Tamoxifen in the prevention and treatment Azathioprine 153 of breast cancer 136 Ciclosporin 154 Selective serotonin re-uptake inhibitors and Cytotoxic drugs 154 withdrawal reactions 136 Asparaginase 157 Triclabendazole and fascioliasis 138 Bleomycin 157 Calcium folinate 157 Chlormethine 158 Current Topics Cisplatin 158 Reverse transcriptase activity in vaccines 140 Cyclophosphamide 158 Consumer protection and herbal remedies 141 Cytarabine 159 Indiscriminate antibiotic
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn Et Al
    US 2004O224012A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn et al. (43) Pub. Date: Nov. 11, 2004 (54) TOPICAL APPLICATION AND METHODS Related U.S. Application Data FOR ADMINISTRATION OF ACTIVE AGENTS USING LIPOSOME MACRO-BEADS (63) Continuation-in-part of application No. 10/264,205, filed on Oct. 3, 2002. (76) Inventors: Pichit Suvanprakorn, Bangkok (TH); (60) Provisional application No. 60/327,643, filed on Oct. Tanusin Ploysangam, Bangkok (TH); 5, 2001. Lerson Tanasugarn, Bangkok (TH); Suwalee Chandrkrachang, Bangkok Publication Classification (TH); Nardo Zaias, Miami Beach, FL (US) (51) Int. CI.7. A61K 9/127; A61K 9/14 (52) U.S. Cl. ............................................ 424/450; 424/489 Correspondence Address: (57) ABSTRACT Eric G. Masamori 6520 Ridgewood Drive A topical application and methods for administration of Castro Valley, CA 94.552 (US) active agents encapsulated within non-permeable macro beads to enable a wider range of delivery vehicles, to provide longer product shelf-life, to allow multiple active (21) Appl. No.: 10/864,149 agents within the composition, to allow the controlled use of the active agents, to provide protected and designable release features and to provide visual inspection for damage (22) Filed: Jun. 9, 2004 and inconsistency. US 2004/0224012 A1 Nov. 11, 2004 TOPCAL APPLICATION AND METHODS FOR 0006 Various limitations on the shelf-life and use of ADMINISTRATION OF ACTIVE AGENTS USING liposome compounds exist due to the relatively fragile LPOSOME MACRO-BEADS nature of liposomes. Major problems encountered during liposome drug Storage in vesicular Suspension are the chemi CROSS REFERENCE TO OTHER cal alterations of the lipoSome compounds, Such as phos APPLICATIONS pholipids, cholesterols, ceramides, leading to potentially toxic degradation of the products, leakage of the drug from 0001) This application claims the benefit of U.S.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Eperisone-Induced Anaphylaxis: Pharmacovigilance Data and Results of Allergy Testing
    Allergy Asthma Immunol Res. 2019 Jan;11(1):e18 https://doi.org/10.4168/aair.2019.11.e18 pISSN 2092-7355·eISSN 2092-7363 Original Article Eperisone-Induced Anaphylaxis: Pharmacovigilance Data and Results of Allergy Testing Kyung Hee Park,1,2 Sang Chul Lee,1,2 Ji Eun Yuk,2 Sung-Ryeol Kim,1,2 Jae-Hyun Lee,1,2 Jung-Won Park1,2* 1Division of Allergy and Immunology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea 2Institute of Allergy, Yonsei University College of Medicine, Seoul, Korea Received: Aug 6, 2018 ABSTRACT Revised: Sep 10, 2018 Accepted: Sep 22, 2018 Purpose: Eperisone is an oral muscle relaxant used in musculoskeletal disorders causing Correspondence to muscle spasm and pain. For more effective pain control, eperisone is usually prescribed Jung-Won Park, MD, PhD together with nonsteroidal anti-inflammatory drugs (NSAIDs). As such, eperisone may Division of Allergy and Immunology, have been overlooked as the cause of anaphylaxis compared with NSAIDs. This study aimed Department of Internal Medicine, Yonsei to analyze the adverse drug reaction (ADR) reported in Korea and suggest an appropriate University College of Medicine, 50-1 Yonsei-ro, diagnostic approach for eperisone-induced anaphylaxis. Seodaemun-gu, Seoul 03722, Korea. Tel: +82- 2-2228-1961; Fax: +82-2-393-6884; Methods: We reviewed eperisone-related pharmacovigilance data (Korea Institute of Drug E-mail: [email protected] Safety-Korea Adverse Event Reporting System [KIDS-KAERS]) reported in Korea from 2010 to 2015. ADRs with causal relationship were selected. Clinical manifestations, severity, Copyright © 2019 The Korean Academy of outcomes, and re-exposure information were analyzed.
    [Show full text]
  • Ovid MEDLINE(R)
    Supplementary material BMJ Open Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily <1946 to September 16, 2019> # Searches Results 1 exp Hypertension/ 247434 2 hypertens*.tw,kf. 420857 3 ((high* or elevat* or greater* or control*) adj4 (blood or systolic or diastolic) adj4 68657 pressure*).tw,kf. 4 1 or 2 or 3 501365 5 Sex Characteristics/ 52287 6 Sex/ 7632 7 Sex ratio/ 9049 8 Sex Factors/ 254781 9 ((sex* or gender* or man or men or male* or woman or women or female*) adj3 336361 (difference* or different or characteristic* or ratio* or factor* or imbalanc* or issue* or specific* or disparit* or dependen* or dimorphism* or gap or gaps or influenc* or discrepan* or distribut* or composition*)).tw,kf. 10 or/5-9 559186 11 4 and 10 24653 12 exp Antihypertensive Agents/ 254343 13 (antihypertensiv* or anti-hypertensiv* or ((anti?hyperten* or anti-hyperten*) adj5 52111 (therap* or treat* or effective*))).tw,kf. 14 Calcium Channel Blockers/ 36287 15 (calcium adj2 (channel* or exogenous*) adj2 (block* or inhibitor* or 20534 antagonist*)).tw,kf. 16 (agatoxin or amlodipine or anipamil or aranidipine or atagabalin or azelnidipine or 86627 azidodiltiazem or azidopamil or azidopine or belfosdil or benidipine or bepridil or brinazarone or calciseptine or caroverine or cilnidipine or clentiazem or clevidipine or columbianadin or conotoxin or cronidipine or darodipine or deacetyl n nordiltiazem or deacetyl n o dinordiltiazem or deacetyl o nordiltiazem or deacetyldiltiazem or dealkylnorverapamil or dealkylverapamil
    [Show full text]
  • Pharmaceuticals Appendix
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ADAPALENE 106685-40-9 ABANOQUIL 90402-40-7 ADAPROLOL 101479-70-3 ABECARNIL 111841-85-1 ADEMETIONINE 17176-17-9 ABLUKAST 96566-25-5 ADENOSINE PHOSPHATE 61-19-8 ABUNIDAZOLE 91017-58-2 ADIBENDAN 100510-33-6 ACADESINE 2627-69-2 ADICILLIN 525-94-0 ACAMPROSATE 77337-76-9 ADIMOLOL 78459-19-5 ACAPRAZINE 55485-20-6 ADINAZOLAM 37115-32-5 ACARBOSE 56180-94-0 ADIPHENINE 64-95-9 ACEBROCHOL 514-50-1 ADIPIODONE 606-17-7 ACEBURIC ACID 26976-72-7 ADITEREN 56066-19-4 ACEBUTOLOL 37517-30-9 ADITOPRIME 56066-63-8 ACECAINIDE 32795-44-1 ADOSOPINE 88124-26-9 ACECARBROMAL 77-66-7 ADOZELESIN 110314-48-2 ACECLIDINE 827-61-2 ADRAFINIL 63547-13-7 ACECLOFENAC 89796-99-6 ADRENALONE 99-45-6 ACEDAPSONE 77-46-3 AFALANINE 2901-75-9 ACEDIASULFONE SODIUM 127-60-6 AFLOQUALONE 56287-74-2 ACEDOBEN 556-08-1 AFUROLOL 65776-67-2 ACEFLURANOL 80595-73-9 AGANODINE 86696-87-9 ACEFURTIAMINE 10072-48-7 AKLOMIDE 3011-89-0 ACEFYLLINE CLOFIBROL 70788-27-1
    [Show full text]
  • Sándor Farkas, MD
    ANALYSIS OF PHARMACODYNAMICS OF TOLPERISONE-TYPE CENTRALLY ACTING MUSCLE RELAXANTS IN NON-CLINICAL STUDIES AND RESEARCH INTO PRECLINICAL MODELLING OF MIGRAINE Dissertation for the degree of Doctor of Philosophy (PhD) Sándor Farkas, MD Doctoral School of Pharmaceutical Sciences Neuropharmacology Programme Doctoral School Leader: Prof. Dr. Erika Pintér Programme Leader: Prof. Dr. Erika Pintér Supervisor: Prof. Dr. Zsuzsanna Helyes Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, University of Pécs Pécs, 2016 Table of contents 1 Chapter 1: Pharmacodynamics of tolperisone-type centrally acting muscle relaxants .............. 3 1.1 Introduction .............................................................................................................................. 3 1.1.1 General objectives ............................................................................................................ 3 1.1.2 Specific objectives of the studies ..................................................................................... 3 1.2 Methods ................................................................................................................................... 4 1.2.1 Neuropharmacological studies on efficacy and side effects in mice ............................... 4 1.2.2 Instrumental neurophysiological studies in unconscious cats ......................................... 6 1.2.3 Instrumental neurophysiological studies in unconscious rats ......................................... 7 1.2.4 Studies in the isolated
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Tolperisone: a Typical Representative of a Class of Centrally Acting Muscle Relaxants with Less Sedative Side Effects
    REVIEW Tolperisone: A Typical Representative of a Class of Centrally Acting Muscle Relaxants with Less Sedative Side Effects Stefan Quasthoff,1 Claudia Mockel,¨ 2 Walter Zieglgansberger,¨ 3 and Wolfgang Schreibmayer4 1 Department for Neurology, Medical University of Graz, Austria 2 Strathmann GmbH & Co. KG, Hamburg, Germany 3 Max Planck Institute of Psychiatry, Munich, Germany 4 Institute for Biophysics, Centre for Physiological Medicine, Medical University of Graz, Austria Keywords Tolperisone, a piperidine derivative, is assigned to the group of centrally acting Stroke; Neuropsychopharmacology; muscle relaxants and has been in clinical use now for decades. The review Neuromuscular disease; Movement disorders; summarizes the known pharmacokinetics, pharmacodynamics, toxicology and Parkinson’s disease; Behavioural neurology; Painful muscle spasm. side effects in humans and the clinical use of tolperisone. A future perspective forfurtherexplorationofthisdrugisgiven. Correspondence Univ. Prof. Dr Phil. Wolfgang Schreibmayer, Institute for Biophysics, Centre for Physiological Medicine, Medical University of Graz Harrachgasse 21/4, A-8010 Graz, Austria. Tel.: +0043 316 380 4155; Fax: +0043 316 380 69 4155; E-mail: [email protected] doi: 10.1111/j.1527-3458.2008.00044.x artine) was achieved, starting from the structure of Introduction cocaine and the first pharmacological experiments, Generally, muscle relaxants are used to achieve re- indicating a central action of the drug, were performed versible relaxation of skeletal muscle. The term “muscle (Porszasz et al. 1961). Several related compounds exist: relaxant” refers to drugs belonging to a group of med- eperisone (E-646, EMPP, Mional, Myonal), lanperisone ications that are heterogeneous with respect to their (NK-433), inaperisone (HY-770), and silperisone (RGH- chemical structure as well as their molecular targets.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2019 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]